Bishal Gyawali/scri.queensu.ca
May 14, 2025, 08:15
Bishal Gyawali: The validity of DFS as a surrogate endpoint for OS in pancreatic cancer trials
Bishal Gyawali, Associate Professor at Queen’s University, shared on LinkedIn:
“Have you read our new paper in BMJ Oncology?
In this paper, we study the validity of DFS as a surrogate endpoint for OS in (Neo) adjuvant pancreatic cancer trials. An important project led by the brilliant Luis Felipe Leite da Silva, a medical student from Brazil.”
Title: Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis
Authors: Luís Felipe Leite, Luiz F Costa de Almeida, Lucas Diniz da Conceição, Mariana Macambira Noronha, Marcos Belotto, Erick F Saldanha, Thais Baccili Cury Megid, Renata D’Alpino Peixoto, Bishal Gyawali
Read the Full Article in BMJ Oncology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 14, 2025, 07:05
May 14, 2025, 06:50
May 14, 2025, 06:45